Damage to the lungs as an adverse effect of a medication
Aetiology
Causative agents include amiodarone, nitrofurantoin, methotrexate, bleomycin, busulfan and sulfasalazine
Patients likely to develop DILD are those receiving chemotherapy, those with inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease, and those receiving concurrent multiple toxic agents
Clinical features
May have a myriad of presentations, ranging from an ARDS-type picture to established pulmonary fibrosis
Management depends on severity of disease - usually involves supportive care
Medication should be stopped/changed to limit progression of the fibrosis, however this is unlikely to dramatically improve the symptoms or degree of fibrosis